Trehalose
- Generic Name
- Trehalose
- Drug Type
- Small Molecule
- Chemical Formula
- C12H22O11
- CAS Number
- 99-20-7
- Unique Ingredient Identifier
- B8WCK70T7I
- Background
Cabaletta has been used in trials studying the treatment of Oculopharyngeal Muscular Dystrophy.
Inflammation Reduction by TREhalose AdminisTration
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Mashhad University of Medical Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT03700424
- Locations
- 🇮🇷
Ghaem Educational, Research and Treatment Center, Mashhad, Razavi Khorasan, Iran, Islamic Republic of
Trehalose as add-on Therapy in Bipolar Depression
- Conditions
- Bipolar DepressionBipolar Disorder
- Interventions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
- Target Recruit Count
- 60
- Registration Number
- NCT02800161
- Locations
- 🇪🇸
Hospital Clinic of Barcelona, Barcelona, Spain
A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects
- Conditions
- Healthy Volunteer Subjects
- Interventions
- Drug: Saline 0.9% IV
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02725957
- Locations
- 🇺🇸
PAREXEL Baltimore Early Phase Clinical Unit; Harbor Hospital, Baltimore, Maryland, United States
Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
- Conditions
- Machado-Joseph Disease / Spinocerebellar Ataxia 3
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT02147886
- Locations
- 🇮🇱
Meir Medical Center, Kfar Saba, Israel
Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02015481
- Locations
- 🇨🇦
Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
🇺🇸UCLA, Los Angeles, California, United States
🇮🇱Hadassah medical center, Jerusalem, Israel
Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- University of Colorado, Boulder
- Target Recruit Count
- 110
- Registration Number
- NCT01575288
- Locations
- 🇺🇸
University of Colorado, Boulder Clinical Translational Research Center, Boulder, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.